Compare MobilEye Global Inc (MBLY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Neurocrine Biosciences Inc — how do they compare? MobilEye Global Inc trades at $9.07 (market cap $7.54B), while Neurocrine Biosciences Inc trades at $177.87 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.3× MobilEye Global Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| MBLY | NBIX | |
|---|---|---|
Market Cap | $7.54B | $17.40B |
Sector | Technology | Health |
52-Week High | $16.19 | $180.55 |
52-Week Low | $6.56 | $123.10 |
Enterprise Value | $6.19B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $8.95, down 2.93% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $392 million in 2025 despite revenue of $1.89 billion, reflecting negative profit margins. Recent news highlights its strategic shift toward launching a vertically integrated U.S. robotaxi service in 2027, generating significant media attention and analyst coverage.
The outlook hinges on execution of its robotaxi initiative, offering growth potential but carrying high execution risk. Analyst consensus is bullish with a $10.71 price target, yet profitability challenges and competitive pressures pose substantial risks. Investors should weigh the long-term transformation against current financial weakness.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
